Atogepant: Optimizing Migraine Prevention with Pharmacokinetics

Research Summary

Researchers developed a population pharmacokinetic model for atogepant, an oral medication for preventing migraines. Utilizing data from 12 phase 1 studies, 1 phase 2b/3 study, and 1 phase 3 study, the model was validated with additional phase 3 data. It highlighted factors affecting atogepant's pharmacokinetics, including dose, formulation, body weight, liver function, and food intake. Notably, severe hepatic impairment and certain medications altered drug clearance significantly. Despite these variables, no significant pharmacokinetic differences were found between healthy individuals and migraine sufferers. Importantly, no dosage adjustments are needed for factors like age, sex, race, or specific medications. The model aids drug development and regulatory decisions, offering insights for healthcare professionals.

Study Details

📄 Title: Population Pharmacokinetics of Atogepant for the Prevention of Migraine.

👥 Research Team: Schlachter L et al.

📚 Published In: Clin Pharmacokinet

📅 Publication Date: 2025 Nov 12

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.